Posted by Michael Wonder on 13 Nov 2023
Outcome statement - September 2023 DUSC meeting
13 November 2023 - The Outcome Statement from the September 2023 DUSC meeting is now available.
The DUSC reviewed the utilisation of the following PBS listed medicines in September 2023:
- Dupilumab (atopic dermatitis)
- Venetoclax (chronic lymphocytic leukaemia/non-Hodgkin's lymphoma)
- Apremilast (psoriasis)
- Lisdexamphetamine dimesylate (attention deficit-hyperactivity disorder)
